Triveni Bio Inc., a US-based biotech company developing a genetics-informed precision medicine approach to develop treatments for immunological and inflammatory (I&I) disorders, announced on Wednesday that Bhaskar Srivastava, M.D., Ph.D., has joined the company as chief medical officer (CMO).
Triveni says that Dr Srivastava will play a critical role as it advances its lead asset (TRIV-509) into the clinic in the first half of 2025 and brings second-generation combination approaches into the clinic in 2026.
The company claims that TRIV-509 - a half-life extended monoclonal antibody inhibitor of both kallikreins (KLK) 5 and 7 - has demonstrated superior efficacy relative to IL-4R inhibition in multiple atopic dermatitis animal models.
'We are thrilled to welcome Bhaskar to the team,' said Vishal Patel, Ph.D., Triveni Bio chief executive officer. 'He arrives at a key moment for the company, equipped with an impressive track record of leading dermatology strategy and clinical programs. Bhaskar's extensive training as a dermatologist and immunologist will further our goal of bringing innovation for I&I diseases.'
Prior to joining Triveni Bio, Dr Srivastava served as senior vice president, Clinical Development at Nimbus Therapeutics, where he advanced several novel clinical programs. Before Nimbus, he held senior clinical development roles at the Johnson & Johnson Innovative Medicine (formerly known as Janssen Pharmaceuticals), developing early-phase clinical programs in dermatology and rheumatology. A board-certified dermatologist, Dr Srivastava practiced medicine as an assistant professor of Dermatology at the Yale School of Medicine.
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Shenzhen Chipscreen Biosciences' IND application for CS231295 tablets accepted in China
Sanofi and Orano partner to advance radioligand therapies
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient